Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs
alzecurepharma.se

See what CB Insights has to offer

Stage

IPO | IPO

Date of IPO

11/28/2018

About AlzeCure Pharma

AlzeCure Pharma is a Swedish pharmaceutical company with a primary focus on Alzheimer's disease. The company is developing five drug candidates within its two main research programs, NeuroRestore och Alzstatin.

AlzeCure Pharma Headquarter Location

Hälsovägen 7 Novum, Floor 7

Huddinge, 141 57,

Sweden

Latest AlzeCure Pharma News

AlzeCure receives phase I trial approval

Sep 1, 2021

AlzeCure receives phase I trial approval Search for content, post, videos AlzeCure Pharma has received approval from the regulatory authorities in Sweden to begin the next clinical phase I study (multiple ascending dose, MAD) with the candidate drug ACD856 focused on Alzheimer’s disease. “This is a statement of strength that shows that AlzeCure continues to deliver according to plan,” says Martin Jönsson, CEO of AlzeCure Pharma. “Diseases with cognitive disorders, and especially Alzheimer’s disease, are areas with high need of new, more effective treatments and I am very much looking forward to the continued development of this important candidate drug.” AlzeCure’s third clinical study with ACD856 The MAD Phase I study is AlzeCure’s third clinical study with ACD856, the lead candidate drug within the company’s NeuroRestore platform. ACD856 is being developed as a symptom-relieving treatment for disease states where the cognitive ability is impaired, such as in Alzheimer’s disease. The primary study goal is to evaluate ACD856’s tolerability and safety after repeated dosing, as well as to examine early signals on brain activity. The substances in the NeuroRestore platform stimulate several important signaling pathways in the brain, which, among other things, leads to improved cognition. Preclinical studies have shown that AlzeCure’s candidate drugs strengthen the communication between nerve cells and improve cognitive ability including memory functions, the company states. Photo: iStock

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing AlzeCure Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

AlzeCure Pharma is included in 1 Expert Collection, including Neuroscience.

N

Neuroscience

2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

AlzeCure Pharma Patents

AlzeCure Pharma has filed 3 patents.

The 3 most popular patent topics include:

  • Developmental neuroscience
  • Experimental cancer drugs
  • Growth factors
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/21/2017

Tyrosine kinase receptors, Transcription factors, Tyrosine kinases, Developmental neuroscience, Proteins

Application

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

12/21/2017

00/00/0000

00/00/0000

Grant Date

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Related Topics

Tyrosine kinase receptors, Transcription factors, Tyrosine kinases, Developmental neuroscience, Proteins

Subscribe to see more

Subscribe to see more

Status

Application

Subscribe to see more

Subscribe to see more

AlzeCure Pharma Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

AlzeCure Pharma Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.